Oral apoAI mimetic peptides like 6 F (Tg6F) directly bind not only bioactive lipids [8,72,73] but also microbial products like LPS to alter intestinal immune cells and the expression of genes including IFNβ1 and MX1 levels, leading to similar changes in lung and reduced lung disease such as cancer [11]. This evidence concerns the gene MX1 and lung disorder.